Epigenomics Posts 6 Percent Q3 Revenues Increase, Eyes FDA Submission for Colorectal Cancer Test by Year End | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today reported a 6 percent increase year over year in third-quarter revenues.

The Berlin, Germany-based firm said that for the three months ended Sept. 30 revenues totaled €272,000 ($347,000), up from €257,000 a year ago as an increase in R&D service fees offset a decrease in licensing revenues.

Epigenomics' net loss narrowed to €3.7 million, or €.42 per share, compared to a net loss of €4.8 million, or €.55 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.